Association Between Opioid Tapering and Subsequent Health Care Use, Medication Adherence, and Chronic Condition Control
JAMA Network Open · 07.02.2023 · 6 (2) · e2255101
DOI: 10.1001/jamanetworkopen.2022.55101 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA Network Open, online erschienen am 07.02.2023. Verfasst von Elizabeth M Magnan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Family and Community Medicine, University of California, Davis, Sacramento. Hauptthemen laut MEDLINE: Analgesics, Opioid, Chronic Disease, Medication Adherence, Drug Tapering. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAMS NIH HHS, NICHD NIH HHS.
Abstract (Originalsprache)
Importance Opioid tapering has been associated with negative consequences, such as increased overdoses and mental health needs. Tapering could also alter use of health care services and worsen care of comorbid conditions through disruption in primary care.
Objective
To evaluate tapering of stable long-term opioid therapy (LTOT) and subsequent health care service use and chronic condition care. Design, Setting, and Participants A retrospective cohort study was conducted from January 1, 2008, to December 31, 2019. Data analysis was performed from July 9, 2020, to December 9, 2022. Data from the Optum Labs Data Warehouse, which contains deidentified retrospective administrative claims data and linked electronic health record data for commercial and Medicare Advantage enrollees, were used. Adults aged 18 years or older prescribed stable doses of LTOT at 50 morphine milligram equivalents or more per day during a 12-month baseline period were included, including subcohorts with hypertension or diabetes. Exposures Opioid tapering, with 15% or more relative reduction in mean daily dose in 6 overlapping periods during 6 months. Main Outcomes and Measures Emergency department visits, hospitalizations, primary care and specialist visits, antihypertensive or antiglycemic medication adherence, and blood pressure and hemoglobin A 1c levels during up to 12 months’ follow-up. Covariates included sociodemographic characteristics, comorbidities, health care use, and chronic condition control.
Results
Among 113 604 patients (60 764 [53.5%] women; mean [SD] age, 58.1 [11.8] years) prescribed LTOT, 41 207 had hypertension and 23 335 had diabetes; in all cohorts, approximately half were women, and half were aged 50 to 65 years. In the overall cohort, tapering was associated with more emergency department visits (adjusted incidence rate ratio [aIRR], 1.19; 95% CI, 1.16-1.21) and hospitalizations (aIRR, 1.16; 95% CI, 1.12-1.20), with similar magnitude associations in the hypertension and diabetes subcohorts. Tapering was associated with fewer primary care visits in the overall cohort (aIRR, 0.95; 95% CI, 0.94-0.96) and hypertension subcohort (aIRR, 0.98; 95% CI, 0.97-0.99). For the hypertension or diabetes subcohorts, tapering was associated with reduced medication adherence (hypertension: aIRR, 0.60; 95% CI, 0.59-0.62; diabetes: aIRR, 0.69; 95% CI, 0.67-0.71) and small increases in diastolic blood pressure and hemoglobin A 1c level. Conclusions and Relevance In this cohort study of patients prescribed LTOT, opioid tapering was associated with more emergency department visits and hospitalizations, fewer primary care visits, and reduced antihypertensive and antidiabetic medication adherence. These outcomes may represent unintended negative consequences of opioid tapering for policy makers and clinicians to consider.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Family and Community Medicine, University of California, Davis, Sacramento.
- Center for Healthcare Policy and Research, University of California, Davis, Sacramento.
- Department of Pediatrics, University of California, Davis, Sacramento.
Förderung
- NIAMS NIH HHS
- NICHD NIH HHS
Zitieren
APA
Magnan, E. M., Tancredi, D. J., Xing, G., Agnoli, A., Jerant, A., & Fenton, J. J. (2023). Association Between Opioid Tapering and Subsequent Health Care Use, Medication Adherence, and Chronic Condition Control. JAMA Network Open, 6(2), e2255101. https://doi.org/10.1001/jamanetworkopen.2022.55101
Vancouver
Magnan EM, Tancredi DJ, Xing G, Agnoli A, Jerant A, Fenton JJ. Association Between Opioid Tapering and Subsequent Health Care Use, Medication Adherence, and Chronic Condition Control. JAMA Network Open. 2023;6(2):e2255101. doi:10.1001/jamanetworkopen.2022.55101
BibTeX
@article{Magnan2023,
author = {Magnan, Elizabeth M and Tancredi, Daniel J and Xing, Guibo and Agnoli, Alicia and Jerant, Anthony and Fenton, Joshua J},
title = {Association Between Opioid Tapering and Subsequent Health Care Use, Medication Adherence, and Chronic Condition Control},
journal = {JAMA Network Open},
year = {2023},
volume = {6},
number = {2},
pages = {e2255101},
doi = {10.1001/jamanetworkopen.2022.55101}
}
EUVIMED